Alnylam Pharma To Receive $25 Mln Payment From Regeneron On FDA Approval Of Livsayis
Alnylam Pharma (ALNY) announced FDA approval of Livsayis for treating generalized myasthenia gravis. The company will receive a $25 million payment from Regeneron and is eligible for royalties. Alnylam shares rose 0.76% in pre-market trading.
How this was made
The 30-second read
Why it matters
The FDA approval triggers a contractual $25 million payment to Alnylam and establishes a potential royalty stream up to 15% on global net sales, improving the probability-weighted cash flow outlook.
Market read
A same-day FDA approval with explicit milestone and royalty terms is a tradable catalyst for ALNY, consistent with the reported pre-market uptick.
What to watch
Royalty upside depends on uptake in the anti-AChR antibody-positive generalized myasthenia gravis segment and competitive dynamics; the article does not provide sales forecasts or timeline for commercialization.
Background
Livsayis was discovered by Alnylam, advanced into Phase 2 by Alnylam, and later moved into an RNAi collaboration where Regeneron took over development, manufacturing, and commercialization.
Ticker impact
Alnylam says the FDA approved Livsayis for generalized myasthenia gravis and that it will receive a $25 million approval payment plus up to 15% royalties.
Likely upward pressure as traders price in the approval milestone and potential royalty stream from global net sales.
The article is a direct, company-specific regulatory approval with concrete financial terms (approval payment and royalty rate cap), which typically drives immediate biotech sentiment and expectations for future cash flows.
Market effects
Reinforces RNAi platform validation and may modestly improve sentiment toward RNAi-focused biotech peers.
Primarily US biotech sentiment via Nasdaq-listed ALNY reaction.
US FDA approval can influence global commercialization expectations and partner royalty economics.
Counterpoint
The $25 million milestone is relatively small versus broader revenue expectations, so the stock reaction may fade if investors focus on longer-term sales ramp uncertainty.
Key entities
- companyAlnylam Pharmaceuticals
US-listed RNAi therapeutics company receiving an FDA approval milestone and royalties tied to Livsayis.
- companyRegeneron
Partner that assumed sole responsibility for Livsayis development, manufacturing, and commercialization.
- productLivsayis
FDA-approved treatment for generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody-positive.
- regulatorFDA
Regulatory body that approved Livsayis, triggering milestone and royalty terms.


